拜瑞妥效果怎么样？

(Rivaroxaban) was first launched in Canada in September 2008 and was approved by the European Union in October. It was marketed by Johnson & Johnson in the United States in July 2001. In June 2009, Xarelto was officially launched in China under the trade name Xarelto. It is used to prevent or reduce the formation of blood clots, deep vein thrombosis (DVT) and pulmonary embolism (PE) after hip or knee replacement surgery. At present, Xarelto has been approved in more than 100 countries around the world, and has been successfully launched by Bayer in more than 75 countries. Today we will learn more about the effect of Xarelto?

Compare the clinical efficacy and safety of Xarelto (rivaroxaban) and low molecular weight heparin sodium injection combined with low molecular weight dextran amino acid injection in the treatment of acute peripheral deep vein thrombosis of the lower limbs. 112 patients with acute peripheral deep vein thrombosis in the lower limbs were randomly divided into a control group and an experimental group, with 56 cases in each group.

The control group received low molecular weight dextran amino acid injection 500 mL each time, qd, intravenous drip + low molecular weight heparin sodium injection 0.4 mL each time, bid, subcutaneous injection; the experimental group received low molecular weight dextran amino acid injection 500 mL each time, qd, intravenous infusion + Xarelto 15 mg each time, bid, orally. Patients in both groups were treated for 10 days. Compare the clinical efficacy, degree of swelling and pain of the affected limb, and the occurrence of adverse drug reactions between the two groups of patients. 

Results After treatment, the total effective rates of the experimental group and the control group were 92. 86% (52 cases/56 cases) and 96. 43% (54 cases/56 cases) respectively, and the difference was not statistically significant (P> 0. 05). After treatment, the swelling degrees of the test group and the control group were (0. 87 ± 0. 45) and (0. 96 ± 0. 47) cm respectively, the pain scores were (2. 19 ± 0. 69) and (2. 35 ± 0. 62) points, respectively, and the whole blood viscosity was (9. 85 ± 2. 94) and (9. 67 ± 2. 91) m respectively. Pa · s, plasma viscosity were (1. 41 ± 0. 31) and (1. 37 ± 0. 33) m Pa · s respectively, and hematocrit were (56. 52 ± 5. 21) % and (55. 49 ± 5. 04) % respectively. The differences were not statistically significant (all P> 0. 05). 

The adverse drug reactions that occurred in the test group included nausea and vomiting and gum bleeding, while those in the control group included nausea and vomiting, gum bleeding and a slight increase in transaminases. The total incidence rates of adverse drug reactions in the experimental group and the control group were 3. 57% and 5. 36% respectively, and the difference was not statistically significant (P> 0. 05). Conclusion: The clinical efficacy and safety of Xarelto (rivaroxaban) combined with low molecular weight dextran amino acid injection and low molecular weight heparin sodium injection combined with low molecular weight dextran amino acid injection in the treatment of acute peripheral deep vein thrombosis of the lower limbs are similar.

The above is the content of the therapeutic effect of (Rivaroxaban), I hope it can help you!

Recommended related hot articles: /newsDetail/76566.html